Full Text View
Tabular View
No Study Results Posted
Related Studies
The Effects of Two Days of Bedrest on Insulin Resistance in Type 2 Diabetics
This study has been completed.
First Received: July 26, 2007   Last Updated: April 22, 2008   History of Changes
Sponsor: University of New Mexico
Information provided by: University of New Mexico
ClinicalTrials.gov Identifier: NCT00508599
  Purpose

The hypothesis of this study is that bed rest in diabetic patients will result in a deterioration of metabolic control (primarily glucose).

Specific aims:

  1. To determine the change in metabolic control in type 2 diabetic individuals when three days of bed rest is compared to three days of activity;
  2. To determine the rate of progression of the deterioration in metabolic control and the magnitude of the decrease;
  3. To assess whether the anticipated deterioration of metabolic control has effects on several parameters of glucose metabolism, including hyperglycemia and hypoglycemia;
  4. To determine the effects of bed rest on surrogate markers of atherosclerosis, such as plasminogen activator inhibitor 1 (PAI1), C-reactive protein (CRP), and homocysteine.
  5. To compare the effects of 48 hours of bed rest on orthostatic responses in type 2 diabetic patients, and healthy non-diabetics.
  6. To make recommendations to the diabetic community to prevent metabolic deterioration during a 3 day hospitalization.

Condition Intervention
Type 2 Diabetes
Insulin Resistance
Other: Study 2 (48 hours of complete bed rest)

Study Type: Interventional
Study Design: Treatment, Randomized, Open Label, Active Control, Crossover Assignment, Safety/Efficacy Study
Official Title: Effect of a 2-Day Bed Rest on Metabolic and Cardiovascular Risk Factors in Type 2 Diabetic Patients

Resource links provided by NLM:


Further study details as provided by University of New Mexico:

Primary Outcome Measures:
  • Insulin resistance and orthostatic response [ Time Frame: 48 hours bed rest and 48 hours activity ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Change in glucose, insulin, and orthostatic impairment. [ Time Frame: 48 hours of bed rest and 48 hours of Activity ] [ Designated as safety issue: No ]

Enrollment: 16
Study Start Date: May 2003
Study Completion Date: February 2006
Primary Completion Date: October 2004 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
1: No Intervention
Study 1 is the control arm in which participants continue with their normal activity.
2.: Experimental
Study 2 consists of 48 hours of complete bed rest.
Other: Study 2 (48 hours of complete bed rest)
Effects of 48 hours of bed rest on insulin resistance in type 2 diabetic subjects.

Detailed Description:

The goal for all diabetic patients is to maintain their metabolic control as close to normal as possible to prevent the short and long term complications of diabetes. Surgery of any type presents a unique challenge to the diabetic patient because two factors tend to worsen their metabolic control 1) the stress of the actual surgery and 2) the bed rest that follows the surgery. Data has clearly shown that surgery increase counter regulatory hormones (epinephrine, glucagon, growth hormone and cortisol). What has not been studied is the effect of bed rest per se on metabolic control. This is surprising because there are many studies in normal healthy people demonstrating that simple bed rest increases insulin resistance and worsens metabolic control.

The proposed study will define the metabolic effects of simple, three-day bed rest on metabolic control in healthy type 2 diabetic volunteers while evaluating the orthostatic response after bed rest. All studies will be done in the inpatient, General Clinical Research Center (GCRC). All volunteers will stop their oral antidiabetic medication before they enter the GCRC. They will be placed on intravenous insulin to prevent severe metabolic deterioration and hyperglycemia. The amount of insulin we have to give them to maintain metabolic control will be one measure of the effects of bed rest on metabolic control.

Experimental Design and Methods.

A crossover study in twenty healthy normal and twenty healthy type 2 diabetic subjects will be utilized. Each subject will be admitted the the GCRC the night prior to beginning the study in order to insure metabolic stability at the start of the protocol. Each subject will stay in the GCRC three full days (three nights) from the time of admission. Each subject will be admitted on two separate occasions, separated by at least a two week interval. A diagram of the protocol is given below:

The primary difference between the two admissions will be the amount of physical activity allowed each subject. On the normal physical activity GCRC admission, the subject will be encouraged to stay our of bed until his/her usual bedtime. All procedures and meals will take place in the GCRC but in between times the subject will be encouraged to walk around the hospital and to carry out normal activities of daily living. On the bed rest GCRC admission, the subjects will be encouraged to stay in bed as much as possible and to use a bedside commode. A tilt test was performed on the morning of the first day of each hospitalization and again 48 hours later. The same testing will be done as in the normal activity admission.

All medications that the volunteer usually takes at home will be continued in the hospital.

The volunteer will be in the GCRC for three days: Day 1, Day 2, and Day 3. The following tests will be done on the three days:

Day 1 - Blood will drawn for fasting lipids, glucose, insulin, and C-peptide as well as surrogate markers of atherosclerosis including PAI-1, IL-6, homocysteine, fibrinogen, and CRP. In addition, a tilt table test will be done to assess autonomic response to activity or bedrest.

Day 2 - Blood will drawn for fasting lipids, glucose, insulin, and C-peptide as well as surrogate markers of atherosclerosis including PAI-1, IL-6, homocysteine, fibrinogen, and CRP.

Day 3 - Blood will drawn for fasting lipids, glucose, insulin, and C-peptide as well as surrogate markers of atherosclerosis including PAI-1, IL-6, homocysteine, fibrinogen, and CRP. In addition, a tilt table test will be done to assess autonomic response to activity or bed rest.

  Eligibility

Ages Eligible for Study:   21 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Type 2 diabetic for at least 6 months.
  • Healthy volunteers.
  • Type 2 diabetic subjects will have some nominal ability to secrete endogenous insulin as demonstrated by a post-stimulation C-peptide concentration of at least 6 ng/ml.
  • All subjects will be mentally fit to give informed consent.
  • Hemoglobin A1C value below 11% (normal range = 4.4-5.8%) prior to study enrollment.

Exclusion Criteria:

  • Hemoglobin A1c values > 11%
  • Severe cardiovascular, hepatic, or renal disease
  • Past current history of drug or alcohol abuse
  • Diabetic gastroparesis
  • Uncontrolled hypertension ( > 140-90 mmHg)
  • Marked hyperlipidemia (serum LDL > 158mg/dl, or serum TG >691 mg/dl)
  • Medications that interfere with glucose homeostasis
  • Coumadin or other anticoagulation medications
  • History of thrombosis or thrombophlebitis
  • Current malignancy
  • Smoker
  • Pregnancy
  • Contact precautions
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00508599

Locations
United States, New Mexico
University of New Mexico, Clinical Translational Science Center
Albuquerque, New Mexico, United States, 87131
Sponsors and Collaborators
University of New Mexico
Investigators
Principal Investigator: David S Schade, M.D. University of New Mexico
  More Information

Publications:
Smorawinski J, Kaciuba-Uscilko H, Nazar K, Kubala P, Kaminska E, Ziemba AW, Adrian J, Greenleaf JE. Effects of three-day bed rest on metabolic, hormonal and circulatory responses to an oral glucose load in endurance or strength trained athletes and untrained subjects. J Physiol Pharmacol. 2000 Jun;51(2):279-89.
Nichiporuk IA, Evdokimov VV, Erasova VI, Smirnov OA, Goncharova AG, Vassilieva GYu, Vorobiev DV. Male reproductive system in conditions of bed-rest in a head-down tilt. J Gravit Physiol. 1998 Jul;5(1):P101-2.
Stuart CA, Shangraw RE, Prince MJ, Peters EJ, Wolfe RR. Bed-rest-induced insulin resistance occurs primarily in muscle. Metabolism. 1988 Aug;37(8):802-6.
Yanagibori R, Suzuki Y, Kawakubo K, Makita Y, Gunji A. Carbohydrate and lipid metabolism after 20 days of bed rest. Acta Physiol Scand Suppl. 1994;616:51-7.
Blanc S, Normand S, Pachiaudi C, Fortrat JO, Laville M, Gharib C. Fuel homeostasis during physical inactivity induced by bed rest. J Clin Endocrinol Metab. 2000 Jun;85(6):2223-33.
Mikines KJ, Richter EA, Dela F, Galbo H. Seven days of bed rest decrease insulin action on glucose uptake in leg and whole body. J Appl Physiol. 1991 Mar;70(3):1245-54.
Yanagibori R, Kondo K, Suzuki Y, Kawakubo K, Iwamoto T, Itakura H, Gunji A. Effect of 20 days' bed rest on the reverse cholesterol transport system in healthy young subjects. J Intern Med. 1998 Apr;243(4):307-12.
Valek J, Valkova L, Vlasakova Z, Topinka V. Increased fibrinogen levels in the offspring of hypertensive men. Relation with hyperinsulinemia and the metabolic syndrome. Arterioscler Thromb Vasc Biol. 1995 Dec;15(12):2229-33.
Gough SC, Rice PJ, McCormack L, Chapman C, Grant PJ. The relationship between plasminogen activator inhibitor-1 and insulin resistance in newly diagnosed type 2 diabetes mellitus. Diabet Med. 1993 Aug-Sep;10(7):638-42.

Additional publications automatically indexed to this study by National Clinical Trials Identifier (NCT ID):
Responsible Party: University of New Mexico ( David S. Schade, M.D. )
Study ID Numbers: 03-163
Study First Received: July 26, 2007
Last Updated: April 22, 2008
ClinicalTrials.gov Identifier: NCT00508599     History of Changes
Health Authority: United States: Institutional Review Board

Keywords provided by University of New Mexico:
type 2 diabetes
bed rest
insulin resistance
insulin
glucose
orthostatic response

Additional relevant MeSH terms:
Hyperinsulinism
Hypoglycemic Agents
Metabolic Diseases
Physiological Effects of Drugs
Diabetes Mellitus, Type 2
Diabetes Mellitus
Endocrine System Diseases
Insulin Resistance
Glucose Metabolism Disorders
Pharmacologic Actions
Insulin

ClinicalTrials.gov processed this record on November 27, 2009